UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19

UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day… Read More

UTRF Inventor Spotlight: Matthew Layne

Local partnership results in creation of new solar charging technology for robotic mowers. One University of Tennessee, Knoxville, staff member sought to solve a problem at work and ended up co-inventing a technology with a local solar company that may unlock new possibilities for the future of electrification. Matthew Layne, co-inventor of a patent-pending, solar-powered… Read More

Discover 2020: UTRF Annual Report

UTRF is delighted to share Discover 2020, which celebrates our innovators and UTRF’s impact on innovation, new venture formation, and corporate engagement for the University of Tennessee. Download accessible PDF.   View past annual reports.  … Read More